On Nov. 19, MIT Technology Review unveiled its list of "50 Smartest Companies" (TR50) of 2020 in Suzhou, China. Thanks to the innovative breakthroughs in oligonucleotide therapeutics, Ribo was shortlisted as a manufacturer of innovative drugs and listed as a TR50 smart company.
Suzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.
Suzhou Ribo Life Science Co., Ltd. announced today that 470 million yuan was raised during its Series C2 financing. In this round of financing, the lead investors included China Venture Capital Fund Corporation Ltd., CICC Qide Fund, and GL Ventures, and the co-investors included renowned investment institutes such as Hengxu Capital, Everest VC, Sinopharm-CICC Capital, Shenzhen Co-way Capital Services Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., and Hongtao Capital
On December 5, 2019, Suzhou Ribo Life Science Co. Ltd., announced the successful completion of Series C1 financing worth RMB 203 million.
Suzhou Ribo Life Science Co., Ltd. today announced that its phase II clinical trial of ISIS449884 Injection, an ASO for the treatment of type 2 diabetes, had completed the enrollment of the first patient and the subject was successfully administered the first dose of study drug.